{"id":23713,"date":"2022-12-09T15:14:00","date_gmt":"2022-12-09T07:14:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23713"},"modified":"2025-01-29T15:18:07","modified_gmt":"2025-01-29T07:18:07","slug":"harbour-biomeds-nona-biosciences-licenses-antibody-platform-to-kelun-biotech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23713","title":{"rendered":"Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech"},"content":{"rendered":"\n

Harbour BioMed (HKG: 2142<\/a>), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio\u2019s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.<\/p>\n\n\n\n

Nona Bio’s Services and Harbour Mice Platform<\/strong>
Nona Bio provides diversified one-stop antibody and antibody-related discovery services such as antigen preparation, animal immunity, single B cell screening, antibody development and engineering, and pharmaceutical and pharmacological evaluations. The Harbour Mice platform allows for the generation of fully human monoclonal antibodies in the classical two light and two heavy chain (H2L2) format and heavy chain only (HCAb) format.<\/p>\n\n\n\n

Kelun-Biotech’s Focus and Pipeline<\/strong>
Kelun-Biotech, focused on oncology, autoimmune diseases, inflammation, metabolic diseases, and more, boasts upwards of 33 novel programs, including 14 in the clinics in China and 3 in the US.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,16,20,190,916,1832,128],"class_list":["post-23713","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cancer","tag-finance","tag-harbour-biomed","tag-hkg-2142","tag-kelun-biotech-biopharmaceutical","tag-nona-biosciences"],"yoast_head":"\nHarbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio\u2019s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23713\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23713\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-09T07:14:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T07:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech\",\"datePublished\":\"2022-12-09T07:14:00+00:00\",\"dateModified\":\"2025-01-29T07:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713\"},\"wordCount\":195,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cancer\",\"Finance\",\"Harbour BioMed\",\"HKG: 2142\",\"Kelun-Biotech Biopharmaceutical\",\"Nona Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23713#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23713\",\"name\":\"Harbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-09T07:14:00+00:00\",\"dateModified\":\"2025-01-29T07:18:07+00:00\",\"description\":\"Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio\u2019s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23713\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23713#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech - Insight, China's Pharmaceutical Industry","description":"Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio\u2019s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23713","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23713","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-09T07:14:00+00:00","article_modified_time":"2025-01-29T07:18:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23713#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23713"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech","datePublished":"2022-12-09T07:14:00+00:00","dateModified":"2025-01-29T07:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23713"},"wordCount":195,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cancer","Finance","Harbour BioMed","HKG: 2142","Kelun-Biotech Biopharmaceutical","Nona Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23713#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23713","url":"https:\/\/flcube.com\/?p=23713","name":"Harbour BioMed's Nona Biosciences Licenses Antibody Platform to Kelun-Biotech - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-09T07:14:00+00:00","dateModified":"2025-01-29T07:18:07+00:00","description":"Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio\u2019s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23713#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23713"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23713#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23713"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23713\/revisions"}],"predecessor-version":[{"id":23714,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23713\/revisions\/23714"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}